Tomas M Eagan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1785255/publications.pdf

Version: 2024-02-01

64 1,682 24
papers citations h-index

66 66 2945
all docs docs citations times ranked citing authors

315739

38

g-index

#	Article	IF	CITATIONS
1	The lower airways microbiome and antimicrobial peptides in idiopathic pulmonary fibrosis differ from chronic obstructive pulmonary disease. PLoS ONE, 2022, 17, e0262082.	2.5	4
2	Performance of Five Metagenomic Classifiers for Virus Pathogen Detection Using Respiratory Samples from a Clinical Cohort. Pathogens, 2022, 11, 340.	2.8	4
3	Factors associated with coronary heart disease in COPD patients and controls. PLoS ONE, 2022, 17, e0265682.	2.5	1
4	Clinical information predicting severe obstructive sleep apnea: A cross-sectional study of patients waiting for sleep diagnostics. Respiratory Medicine, 2022, 197, 106860.	2.9	4
5	Coagulation markers as predictors for clinical events in <scp>COPD</scp> . Respirology, 2021, 26, 342-351.	2.3	28
6	Exploring protocol bias in airway microbiome studies: one versus two PCR steps and 16S rRNA gene region V3 V4 versus V4. BMC Genomics, 2021, 22, 3.	2.8	11
7	The pulmonary mycobiomeâ€"A study of subjects with and without chronic obstructive pulmonary disease. PLoS ONE, 2021, 16, e0248967.	2.5	16
8	Characteristics of 24-hourÂambulatory blood pressure monitoring in a COVID-19 survivor. Future Cardiology, 2021, 17, 1321-1326.	1.2	8
9	One Year Change in 6-Minute Walk Test Outcomes is Associated with COPD Prognosis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2020, 17, 662-671.	1.6	7
10	The airway microbiota and exacerbations of COPD. ERJ Open Research, 2020, 6, 00168-2020.	2.6	13
11	ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respiratory Research, 2020, 7, e000598.	3.0	11
12	Complications and discomfort after research bronchoscopy in the MicroCOPD study. BMJ Open Respiratory Research, 2020, 7, e000449.	3.0	9
13	The respiratory virome and exacerbations in patients with chronic obstructive pulmonary disease. PLoS ONE, 2019, 14, e0223952.	2.5	51
14	Laboratory contamination in airway microbiome studies. BMC Microbiology, 2019, 19, 187.	3.3	31
15	Sputum microbiota and inflammation at stable state and during exacerbations in a cohort of chronic obstructive pulmonary disease (COPD) patients. PLoS ONE, 2019, 14, e0222449.	2.5	21
16	Motivation and response rates in bronchoscopy studies. Multidisciplinary Respiratory Medicine, 2019, 14, 14.	1.5	4
17	Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study. Respiratory Medicine, 2019, 152, 81-88.	2.9	24
18	Dynamic differences in dietary polyunsaturated fatty acid metabolism in sputum of COPD patients and controls. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 224-233.	2.4	26

#	Article	IF	CITATIONS
19	Associations between obstructive lung disease and symptoms of obstructive sleep apnoea in a general population. Clinical Respiratory Journal, 2018, 12, 31-39.	1.6	8
20	Guideline adherence in hospital recruited and population based COPD patients. BMC Pulmonary Medicine, 2018, 18, 195.	2.0	9
21	Lung hyperinflation and functional exercise capacity in patients with COPD – a three-year longitudinal study. BMC Pulmonary Medicine, 2018, 18, 187.	2.0	10
22	Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD. European Respiratory Journal, 2017, 49, 1601298.	6.7	38
23	Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease. European Respiratory Journal, 2017, 49, 1601328.	6.7	53
24	Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Research, 2017, 3, 00019-2017.	2.6	34
25	The association of tidal EFL with exercise performance, exacerbations, and death in COPD. International Journal of COPD, 2017, Volume 12, 2179-2188.	2.3	18
26	Median regression spline modeling of longitudinal FEV1 measurements in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) patients. PLoS ONE, 2017, 12, e0190061.	2.5	6
27	A pilot study of hot-wire, ultrasonic and wedge-bellows spirometer inter- and intra-variability. BMC Research Notes, 2017, 10, 497.	1.4	4
28	Comparing microbiota profiles in induced and spontaneous sputum samples in COPD patients. Respiratory Research, 2017, 18, 164.	3.6	24
29	Incidence of utilization- and symptom-defined COPD exacerbations in hospital- and population-recruited patients. International Journal of COPD, 2016, Volume 11, 2099-2108.	2.3	10
30	Change in pulmonary diffusion capacity in a general population sample over 9 years. European Clinical Respiratory Journal, 2016, 3, 31265.	1.5	5
31	Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD. European Respiratory Journal, 2016, 48, 82-91.	6.7	48
32	Macrophage migration inhibitory factor, a role in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1-L7.	2.9	19
33	Diffusion capacity and CT measures of emphysema and airway wall thickness – relation to arterial oxygen tension in COPD patients. European Clinical Respiratory Journal, 2016, 3, 29141.	1.5	10
34	Expert opinion of mediastinal lymph node positions from an intrabronchial view. BMC Pulmonary Medicine, 2016, 16, 15.	2.0	5
35	Variability of within-breath reactance in COPD patients and its association with dyspnoea. European Respiratory Journal, 2015, 45, 625-634.	6.7	31
36	Comparison of inflammatory markers in induced and spontaneous sputum in a cohort of COPD patients. Respiratory Research, 2014, 15, 138.	3.6	28

#	Article	IF	CITATIONS
37	Predictors for P _a O ₂ and Hypoxemic Respiratory Failure in COPD–A Three-Year Follow-up. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 531-538.	1.6	10
38	Productivity losses in chronic obstructive pulmonary disease: a population-based survey. BMJ Open Respiratory Research, 2014, 1, e000049.	3.0	18
39	Paraneoplastic <scp>H</scp> u and <scp>CRMP5</scp> antibodies are present in smokers without cancer or neurological disease. Respirology, 2014, 19, 730-734.	2.3	6
40	Physical activity and longitudinal change in 6-minÂwalk distance in COPD patients. Respiratory Medicine, 2014, 108, 86-94.	2.9	20
41	Inflammatory cytokine response to exercise in alpha-1-antitrypsin deficient COPD patients â€~on' or â€~off' augmentation therapy. BMC Pulmonary Medicine, 2014, 14, 106.	м 2 . 0	10
42	The Bergen COPD microbiome study (MicroCOPD): rationale, design, and initial experiences. European Clinical Respiratory Journal, 2014, 1, 26196.	1.5	21
43	Predictors of Exacerbations in Chronic Obstructive Pulmonary Disease - Results from the Bergen COPD Cohort Study. PLoS ONE, 2014, 9, e109721.	2.5	62
44	Insomnia symptoms, objectively measured sleep, and disease severity in chronic obstructive pulmonary disease outpatients. Sleep Medicine, 2013, 14, 1328-1333.	1.6	27
45	Comparison of 2011 and 2007 Global Initiative for Chronic Obstructive Lung Disease Guidelines for Predicting Mortality and Hospitalization. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 51-59.	5.6	78
46	Non-Response in Telephone Surveys of Copd Patients Does Not Introduce Bias. Journal of Telemedicine and Telecare, 2013, 19, 40-44.	2.7	5
47	The prevalence of undiagnosed renal failure in a cohort of COPD patients in western Norway. Respiratory Medicine, 2012, 106, 361-366.	2.9	33
48	TNF- \hat{l}_{\pm} is associated with loss of lean body mass only in already cachectic COPD patients. Respiratory Research, 2012, 13, 48.	3.6	37
49	Different COPD Disease Characteristics are Related to Different Outcomes in the 6-minute Walk Test. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 227-234.	1.6	23
50	Association of exposure to environmental tobacco smoke in childhood with chronic obstructive pulmonary disease and respiratory symptoms in adults. Respirology, 2012, 17, 499-505.	2.3	46
51	High prevalence of respiratory symptoms during air travel in patients with COPD. Respiratory Medicine, 2011, 105, 50-56.	2.9	31
52	Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: results from the European community respiratory health survey. Health and Quality of Life Outcomes, 2010, 8, 107.	2.4	66
53	Socioeconomic risk factors for lung function decline in a general population. European Respiratory Journal, 2010, 36, 480-487.	6.7	30
54	Body composition and plasma levels of inflammatory biomarkers in COPD. European Respiratory Journal, 2010, 36, 1027-1033.	6.7	31

#	Article	IF	CITATIONS
55	Neutrophil Gelatinase-Associated Lipocalin. Chest, 2010, 138, 888-895.	0.8	89
56	Systemic mannose-binding lectin is not associated with chronic obstructive pulmonary disease. Respiratory Medicine, 2010, 104, 283-290.	2.9	17
57	Response to Leiro et al Respiratory Medicine, 2010, 104, 1387.	2.9	O
58	Occupational exposure and incidence of respiratory disorders in a general population. Scandinavian Journal of Work, Environment and Health, 2009, 35, 454-461.	3.4	24
59	Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulmonary Medicine, 2008, 8, 2.	2.0	61
60	Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respiratory Medicine, 2008, 102, 399-406.	2.9	68
61	Changes in Respiratory Symptoms and Health-Related Quality of Life. Chest, 2007, 131, 1890-1897.	0.8	39
62	Exposure to environmental tobacco smoke in a general population. Respiratory Medicine, 2007, 101, 277-285.	2.9	22
63	The effect of educational level on the incidence of asthma and respiratory symptoms. Respiratory Medicine, 2004, 98, 730-736.	2.9	63
64	Nonresponse in a community cohort study. Journal of Clinical Epidemiology, 2002, 55, 775-781.	5.0	106